# Ozempic's Hidden Powers: Heart Health, Addiction, and Global Access Breakthroughs

0:00Welcome to Navigating OZMPIC, the show where we break down the latest news, science and real-world impact of OZMPIC and other medications in its class. So listeners can make sense of a very fast-moving story in health and lifestyle. Today we are focusing on a wave of new research and policy developments that have landed in just the past few days. These updates touch on everything, from how affordable OZMPIC could eventually become around the world, to surprising new findings about the heart, addiction and what really happens when you stop these medications. Let us start with cost and global access, because that is where so many conversations about OZMPIC begin and end. According to a recent analysis reported by stat news, scientists looking at the raw ingredient costs for semi-glutide, the active compound in OZMPIC found that generic versions of OZMPIC and Wegovie could theoretically be mass-produced for

1:04around $3 per person per month in low and middle income countries once patents expire and competition arrives. The analysis estimated that the active ingredient could be manufactured for between $28 and $140 per year, which is dramatically lower than current retail prices in many high-income markets. The key news is that patents for semi-glutide are starting to expire this month, in countries including India, China, Canada, Brazil and Turkey, with a few more countries to follow later this year. Stat News reports that this is expected to open the door for generic manufacturers, especially in India to begin competing on price and to widen access for diabetes and obesity treatment, far beyond wealthy healthcare systems. For listeners, this raises a big question. If the medication can be made so cheaply, why is it still so expensive at the pharmacy counter? That gap between possible manufacturing cost and actual price is likely to be a major policy

2:05and political issue over the coming year, especially as more countries and insurers struggle to cover demand. It also highlights a growing divide. On one hand, OZMPIC and similar drugs are transforming care for people who can access them. On the other hand, most of the world still cannot afford these treatments at scale, even for diabetes, let alone for obesity. The next major story has to do with the heart, and it suggests that these drugs might do more than help listeners lose weight or control blood sugar. Researchers at the University of Bristol and University College London, in a study covered by Science Daily, have just reported that medications like OZMPIC, WIGOVY and MANGARO may help protect the heart after a heart attack in a very specific way. The study, published in the journal Nature Communications, looked at the complication of heart attacks called no reflow. No reflow happens when doctors successfully reopen a blocked major artery, but the tiny blood vessels deeper in the heart muscles stay narrowed. In up to half

3:06of heart attack patients, this no reflow problem limits blood supply, raises the risk of further damage, and increases the chance of heart failure or death within a year. The Bristol and University College London team found that drugs in the OZMPIC family, known as Glucagan-like peptide one receptor agonists, seemed to relax specialized cells called parasites that sit on those tiny coronary vessels. In animal models, activating the Glucagan-like peptide one pathway opened up these small vessels, improved blood flow, and reduced downstream heart damage. The lead researchers suggest that medications like OZMPIC could be repurposed in the future as part of acute heart attack care specifically to prevent no reflow, not just as chronic diabetes or weight loss drugs.

4:10While this is still early stage and conducted in models rather than large human trials, it adds to growing evidence that these medications have direct cardiovascular benefits that go beyond simply reducing weight or blood sugar levels. Another major thread In the news is the impact of OZMPIC-like drugs on addiction and substance use. Science magazine has just reported on a large study published in the British Medical Journal that analyzed health records for more than 600,000 veterans in the United States. In this study, people with diabetes who were prescribed a Glucagan-like peptide one drug,

5:15such as semi-glutide, were compared to similar patients who used a different diabetes drug class called sodium glucose-co-transporter-2 inhibitors. According to the researchers, those on a Glucagan-like peptide one drug were 14% less likely to develop a new substance use disorder involving alcohol, cannabis, cocaine, nicotine, or opioids. Over three years, patients on these drugs had about 30% fewer drug-related emergency room visits. 25% fewer drug-related hospitalizations and roughly 40% fewer overdoses than those on the comparison medications. Deaths related to substance use were about half as common and suicidal thinking or attempts were lower as well. Experts quoted by Science described these results as exciting, but also caution that this type of observational data cannot prove cause

6:15an effect. It could be that patients on these drugs differ in important ways that the analysis did not fully capture. Still, the findings align with earlier smaller trials suggesting that semi-glutide might reduce alcohol intake in people with alcohol use disorder. Some clinicians are already prescribing these medications off-label for addiction, but addiction researchers stress that current evidence is not strong enough to replace established treatments. What this study does show is that the Glucagan-like peptide-1 system, which ozemic targets, appears to influence reward pathways in the brain in a fairly broad way, possibly dampening cravings not only for food, but for several addictive substances. Larger randomized trials now underway will be critical in determining whether ozemic or related drugs will become formally approved tools in addiction medicine. So, we have heart-prote.